

From: avakado Media <publications@avakado.eu>
Sent: Friday, April 20, 2012 9:22 AM
To: Hanchett, James (DPH)
Subject: Toms Top Ten this week drug discovery collaborations

Problems reading this email? [View in a browser](#)



Click on the arrow or [click here](#) to listen

April 20, 2012:

- [Sanofi and Michael J. Fox Foundation collaborate in Parkinson's disease](#)
- [Roche decides not to extend Illumina tender offer](#)
- [Merck and Endocyte establish exclusive worldwide agreement for cancer candidate vintafolide](#)
- [4SC Discovery and CRELUX form drug discovery services alliance](#)
- [Selcia and Heptares Therapeutics in fragment screening collaboration](#)
- [Enamine extends UkrOrgSynthesis chemical building blocks collaboration](#)
- [Imaxio closes €2.9 million funding round](#)
- [US Supreme Court ruling allows challenge to Novo Nordisk patent submissions for diabetes treatment](#)
- [Abbott licenses biomarkers to differentiate aggressive from non-aggressive prostate cancer](#)
- [Plexpress secures \\$2.3 million to commercialise gene expression analysis platform](#)

Brought to you by:



Tom's Top Ten sponsored by:



This email was sent from avakado Ltd.
To stop receiving further emails, please reply to this message and include unsubscribe in the subject line.
avakado Limited is a company registered in England and Wales. Company number 04186087. VAT Registration Number:GB783470408

UNSUBSCRIBE INFORMATION

This email was sent to james.hanchett@state.ma.us, by avakado Media.

[Opt-out of any future messages here.](#)

We will respect your decision to receive no further emails from us.

